Stock ORX OREXO AB
Add to a list
To use this feature you must be a member
Log inSign up

Orexo AB Stock

Equities

ORX

SE0000736415

Pharmaceuticals

Market Closed - Nasdaq Stockholm
Other stock markets
 12:00:00 2025-01-10 EST 		5-day change 1st Jan Change
19.48 SEK +6.56% Intraday chart for Orexo AB +3.07% +11.31%
01-10 Orexo's Anaphylaxis Treatment Trial Yields Positive Topline Results MT
01-10 Carnegie positive on Orexo's OX640 study results - increased likelihood of partnership agreement FW

Valuation: Orexo AB

Capitalization 672M 59.82M 58.45M 54.89M 49.04M 86.37M 5.15B 97.37M 249M 2.12B 224M 220M 9.44B P/E ratio 2024 *
-4.35x
P/E ratio 2025 * -9.37x
Enterprise value 1.03B 91.29M 89.2M 83.76M 74.83M 132M 7.86B 149M 381M 3.23B 342M 335M 14.41B EV / Sales 2024 *
1.75x
EV / Sales 2025 * 1.62x
Free-Float
78.7%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data

Chart: Orexo AB

Dynamic Chart

Latest news: Orexo AB

Orexo's Anaphylaxis Treatment Trial Yields Positive Topline Results 01-10 MT
Carnegie positive on Orexo's OX640 study results - increased likelihood of partnership agreement 01-10 FW
Orexo announces positive data from clinical study of OX640 01-10 FW
Orexo AB Announces Positive Topline Results from the Clinical Study OX640-002 01-10 CI
Orexo AB Appoints Friedrich Von Bohlen Und Halbach as Board Member 12-18 CI
Orexo, Abera Bioscience to Collaborate on Nasal Powder Vaccines 12-17 MT
Three stocks have set new 52-week highs on the Stockholm Stock Exchange so far today 12-17 FW
Stockholm Bullets - Instalco backs down on savings program 12-17 FW
Orexo starts collaboration with Abera in nasal powder vaccines 12-17 FW
Orexo Enters into Collaboration with Abera to Develop Nasal Powder Vaccines Based on the Amorphox Technology 12-17 CI
Fifth day of losses in Stockholm, OMXS30 index down 0.5 percent 12-16 FW
Stockholm Bullets - Abliva rallies on takeover bid, Proact falls on profit warning and CEO change 12-16 FW
RX Securities lowers target price for Orexo to SEK 40 (50), reiterates Buy - BN 12-16 FW
More news

Last Transcript: Orexo AB

Logo Orexo AB
Orexo AB, Q3 2024 Earnings Call, Oct 24, 2024
24-10-24
More transcripts

Analysts' recommendations: Orexo AB

Carnegie positive on Orexo's OX640 study results - increased likelihood of partnership agreement 01-10 FW
RX Securities lowers target price for Orexo to SEK 40 (50), reiterates Buy - BN 12-16 FW
Carnegie sets motivated value of SEK 15-27 for Orexo - mission analysis 12-13 FW
A broader product portfolio is much needed for Orexo - Penser 24-10-09 FW
Penser lowers motivated value for Orexo - delayed launch of OX124 a disappointment 24-07-18 FW
More recommendations

Press Releases: Orexo AB

Orexo: Positive OX640 read-out 01-10 AQ
Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis 01-10 AQ
Orexo : Report from Orexo AB's extraordinary general meeting, December 18 2024 12-18 PU
Report from Orexo AB’s extraordinary general meeting, December 18 2024 12-18 AQ
Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology 12-17 AQ
More press releases

Quotes and Performance

1 day+6.56%
1 week+3.07%
Current month+11.31%
1 month+7.03%
3 months+41.98%
6 months-2.60%
Current year+11.31%
More quotes

Course Extremes

1 week
18.04
Extreme 18.04
19.58
1 month
16.20
Extreme 16.2
24.00
Current year
17.30
Extreme 17.3
19.58
1 year
9.18
Extreme 9.18
24.00
3 years
8.44
Extreme 8.44
34.30
5 years
8.44
Extreme 8.44
85.70
10 years
8.44
Extreme 8.44
149.25
More quotes

Managers and Directors: Orexo AB

Director TitleAgeSince
Nikolaj Sørensen CEO
 Chief Executive Officer 53 2013-02-04
Fredrik Järrsten DFI
 Director of Finance/CFO 58 2022-08-31
Edward Kim CTO
 Chief Tech/Sci/R&D Officer - 2022-10-25
Manager TitleAgeSince
Staffan Lindstrand BRD
 Director/Board Member 63 2001-12-31
George Wilkinson BRD
 Director/Board Member 69 2019-04-10
James Noble CHM
 Chairman 66 2020-04-15
More insiders

Specialty & Advanced Pharmaceuticals

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi. ($)
OREXO AB Stock Orexo AB
+6.56%+3.07%+31.62%-41.82%59.82M
MERCK KGAA Stock Merck KGaA
+0.39%+1.79%-1.83%-29.78%63.43B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
-1.29%-3.60%-7.88%-27.07%7.38B
YUHAN CORPORATION Stock Yuhan Corporation
+0.75%+12.42%+112.70%+137.13%6.81B
HALOZYME THERAPEUTICS, INC. Stock Halozyme Therapeutics, Inc.
-1.79%+10.60%+53.35%+48.82%6.72B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-1.71%+5.40%+20.02%+23.63%6.12B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
+1.04%+1.51%+12.26%-33.49%2.99B
SUPERNUS PHARMACEUTICALS, INC. Stock Supernus Pharmaceuticals, Inc.
-1.50%+1.54%+32.75%+26.36%2.07B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
-0.72%-4.75%+18.24%+5.05%2.02B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+5.39%+4.20%-39.49%+1.64%1.67B
Average +0.71%+2.53%+23.17%+11.05% 9.93B
Weighted average by Cap. +0.06%+2.63%+11.60%-7.23%
See all sector performances

Financials

2024 *2025 *
Net sales 585M 52.07M 50.87M 47.77M 42.68M 75.17M 4.49B 84.74M 217M 1.84B 195M 191M 8.22B 590M 52.47M 51.27M 48.14M 43.01M 75.75M 4.52B 85.4M 219M 1.86B 197M 193M 8.28B
Net income -154M -13.73M -13.42M -12.6M -11.26M -19.83M -1.18B -22.35M -57.25M -486M -51.51M -50.44M -2.17B -71.5M -6.36M -6.22M -5.84M -5.22M -9.19M -548M -10.36M -26.53M -225M -23.87M -23.38M -1B
Net Debt 354M 31.46M 30.74M 28.87M 25.79M 45.42M 2.71B 51.21M 131M 1.11B 118M 116M 4.97B 285M 25.37M 24.78M 23.27M 20.79M 36.62M 2.19B 41.29M 106M 898M 95.15M 93.17M 4B
More financial data * Estimated data

Company Profile

Logo Orexo AB
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
Employees
113
Sector
Pharmaceuticals
Calendar
2025-02-06 - Q4 2024 Earnings Release
More about the company

Quotes

Date Price Change Volume
25-01-10 19.48 kr +6.56% 48,341
25-01-09 18.28 kr -2.14% 5,775
25-01-08 18.68 kr -3.41% 19,887
25-01-07 19.34 kr +2.33% 40,542

Delayed Quote Nasdaq Stockholm, January 10, 2025 at 12:00 pm

More quotes

Income Statement and Estimates

income-statement-evolution-chart OREXO-AB More financial data

Ratings

Trading Rating
Investor Rating
ESG MSCI
A
surperformance-ratings-light-chart OREXO-ABMore Ratings
Profit revisions
estimates-change-chart OREXO-AB Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart OREXO-AB Company calendar
  1. Stock Market
  2. Equities
  3. ORX Stock
United States

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition